

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box, 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/993,179	11/06/2001	Sean A. McCarthy	MBIO97-018DV1ACN1M	1059
75	90 03/09/2004		EXAMI	NER
Millennium Ph	armaceuticals, Inc.		LAMBERTSO	N, DAVID A
75 Sidney Stree			T	
Cambridge, MA 02139			ART UNIT	PAPER NUMBER
			1636	

DATE MAILED: 03/09/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)
	09/993,179	MCCARTHY ET AL.
Office Action Summary	Examiner	Art Unit
	David A. Lambertson	1636
The MAILING DATE of this communication Period for Reply	on appears on the cover sheet w	ith the correspondence address -
A SHORTENED STATUTORY PERIOD FOR F THE MAILING DATE OF THIS COMMUNICAT - Extensions of time may be available under the provisions of 37 of after SIX (6) MONTHS from the mailing date of this communicat - If the period for reply specified above is less than thirty (30) days - If NO period for reply is specified above, the maximum statutory - Failure to reply within the set or extended period for reply will, by Any reply received by the Office later than three months after the earned patent term adjustment. See 37 CFR 1.704(b).	TION. CFR 1.136(a). In no event, however, may a rition. s, a reply within the statutory minimum of thir period will apply and will expire SIX (6) MON y statute, cause the application to become AE	eply be timely filed by (30) days will be considered timely. ITHS from the mailing date of this communica IANDONED (35 U.S.C. § 133).
Status		
1) Responsive to communication(s) filed on	<u>06 November 2001</u> .	
2a) This action is FINAL . 2b)	This action is non-final.	
3) Since this application is in condition for a	illowance except for formal matt	ers, prosecution as to the merits
closed in accordance with the practice un	nder <i>Ex parte Quayl</i> e, 1935 C.D). 11, 453 O.G. 213.
Disposition of Claims		
4) Claim(s) 18-25 is/are pending in the appl	lication.	
4a) Of the above claim(s) is/are wi	thdrawn from consideration.	
5) Claim(s) is/are allowed.		
6) Claim(s) is/are rejected.		
7) Claim(s) is/are objected to.		
8) Claim(s) <u>18-25</u> are subject to restriction a	and/or election requirement.	
Application Papers		
9) The specification is objected to by the Ex	aminer.	
10) The drawing(s) filed on is/are: a)		by the Examiner.
Applicant may not request that any objection	to the drawing(s) be held in abeyar	nce. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the call. The oath or declaration is objected to by the call.	·	

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) ☐ All b) ☐ Some * c) ☐ None of:

1. Certified copies of the priority documents have been received.

2. Certified copies of the priority documents have been received in Application No. _____.

3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s	s)
--------------	----

	Notice of References Cited (PTO-892)
	Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) 🔲	Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)

4) 📖	Interview Summary (P10-413)
	Paper No(s)/Mail Date

5) Notice of Informal Patent Application (PTO-152)

6)		Other:	
----	--	--------	--

U.S. Patent and Trademark Office PTOL-326 (Rev. 1-04)

Paper No(s)/Mail Date ___

Application/Control Number: 09/993,179

Art Unit: 1636

DETAILED ACTION

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 18-25, drawn to the isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 2, or encoded by the nucleic acid sequence of SEQ ID NO: 1, classified in class 530, subclass 300.
- II. Claims 18-25, drawn to the isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 4, or encoded by the nucleic acid sequence of SEQ ID NO: 3, classified in class 530, subclass 300.

The inventions are distinct, each from the other because of the following reasons:

Inventions Group I and Group II are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions have different functions, and are not disclosed as capable of being used together. Specifically, the inventions of Group I and Group II are distinct amino acid sequences, each with an independent structure-function relationship that is predicated on the distinct amino acid sequence. Because each Group claims a protein that has a distinct amino acid sequence, the Groups have different functions and are considered distinct patentable subject matter.

Pursuant to 35 U.S.C. 121 and 37 C.F.R. 1.141, the sequences listed in claims 18-25 are subject to restriction. The Commissioner has partially waived the requirements of 37 C.F.R. 1.141 and will permit a reasonable number of such amino acid sequences to be

Application/Control Number: 09/993,179

Art Unit: 1636

claimed in a single application. Under this policy, a single independent and distinct sequence will be examined in a single application. Furthermore, a search of more than one (1) of the sequences claimed presents an undue burden on the Patent and Trademark Office due to the complex nature of the search and corresponding examination of more than one (1) of the claimed sequences. In view of the foregoing, one (1) sequence is considered to be a reasonable number of sequences for examination.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper. Furthermore, especially in instances where the classifications are the same, the non-patent literature searches required for each of these inventions are not co-extensive, hence said searches would be burdensome. Therefore restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim

Art Unit: 1636

remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David A. Lambertson whose telephone number is (571) 272-0771. The examiner can normally be reached on 6:30am to 4pm, Mon.-Fri., first Friday off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Remy Yucel, Ph.D. can be reached on (571) 272-0781. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

David A. Lambertson, Ph.D. AU 1636

JAMES KETTER
PRIMARY EXAMINER